Novoeight (turoctocog alfa)

05:23 EST 16th December 2018 | BioPortfolio

Novoeight (turoctocog alfa) is a recombinant coagulation factor VIII.

The FDA approved Novoeight® for use in adults and children with haemophilia A for:

  • Control and prevention of bleeding
  • Perioperative management
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® has been studied in the guardian™ clinical programme; one of the largest and most comprehensive pre-registration clinical trial programmes in the field of haemophilia therapy with more than 210 severe haemophilia A patients. In the completed trials Novoeight® demonstrated good efficacy in preventing and treating bleeds and had no confirmed inhibitor development, and all patients in the surgery trial were treated effectively. Novoeight® will be launched with the newly introduced prefilled device, MixPro®.

For further information:

Quick Search


review and buy Novoeight (turoctocog alfa) market research data and corporate reports here